Table 8.
In situ gelling formulations from modified chitosans (CS).
| Modified CS | Crosslinking Agent | 2nd Polymer | Trigger | Tgel (°C) |
Drug | Ref. |
|---|---|---|---|---|---|---|
| CS-g-PNIPAAm a | - | - | T | 31.9 | Pilocarpine | [266] |
| CS-g-PNIPAAm b | - | - | T | 29.7 | Pilocarpine | [267] |
| Quaternary ammonium CS 20% | β-GP | CS | T | 35 | 5-fluorouracil CS NPss | [178] |
| CS 24
c 3.8% w/w |
β-GP 20% w/w |
- | T | 35 | Dexamethasone- loaded NLC | [269] |
| HexGlyCS d 2% w/w |
- | - | T | 30 | Brimonidine tartrate | [270] |
| CMCS 2% w/v |
β-GP 7.8% w/v |
CS 2% w/v |
T | - | [153] | |
| CMCS 2.5% w/v |
GA | P407 5.0% w/v |
pH, T | 32–33 | Nepafenac | [273] |
| CMCS 3% w/v |
genipin | P407 1% w/v |
pH, T | 37 | Baicalin-loaded NLC | [276] |
| Hydroxybutyl CS 8 mg/mL |
- | - | T | 37 | - | [277] |
PNIPAAm: poly(N-isopropylacrylamide), β-GP: β-glycerolphosphate, NPs: nanoparticles, NLC: nanostructured lipid carriers, HexGlyCS: hexanoyl glycol chitosan, CMCS: carboxymethyl chitosan, GA: glutaraldehyde, P407: poloxamer 407. a: degree 74%, grafting ratio 413, b: deacetylation degree 80%, grafting ratio 161, c: hydroxypropyltrimethyl ammonium chloride CS, d: degree of hexanoylation 39.5%.